The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK

Leukemia. 2016 Oct;30(10):2119-2123. doi: 10.1038/leu.2016.155. Epub 2016 May 25.

Authors

J Rudolph¹, A Heine¹, T Quast², W Kolanus², J Trebicka³, P Brossart¹, D Wolf¹

Affiliations

¹ Medical Clinic 3, Oncology, Hematology, Immunoncology and Rheumatology, University Clinic Bonn (UKB), Bonn, Germany.
² Molecular Immunology & Cell Biology, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany.
³ Department of Internal Medicine I, University Hospital of Bonn, Bonn, Germany.

PMID: 27220666
DOI: 10.1038/leu.2016.155

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cell Movement / drug effects*
Dendritic Cells / pathology*
Humans
Nitriles
Protein Kinase Inhibitors / pharmacology*
Pyrazoles / pharmacology*
Pyrimidines
rho-Associated Kinases / antagonists & inhibitors*

Substances

Nitriles
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
ruxolitinib
rho-Associated Kinases